Access cutting-edge chondrosarcoma treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access chondrosarcoma specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related chondrosarcoma treatment provided free
Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection. IDH1 mutant status will be determined during pre-screening/screening phase. Participant must ha
Sponsor: Servier Bio-Innovation LLC
Check if you qualify for this chondrosarcoma clinical trial in Chicago, IL
If you're searching for chondrosarcoma treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chondrosarcoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.